Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 944

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer

Open access
Braicu, Cornelia, Buse, Mihail, Busuioc, Constantin, Drula, Rares, Gulei, Diana, Raduly, Lajos, Rusu, Alexandru, Irimie, Alexandru, Atanasov, Atanas G., Slaby, Ondrej, Ionescu, Calin, Berindan-Neagoe, Ioana·2019·Cancers

Abstract

The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch from extracellular signals to intracellular responses. Alterations of signaling cascades are found in various diseases, including cancer, as a result of genetic and epigenetic changes. Numerous studies focused on both the homeostatic and the pathologic conduct of MAPK signaling; however, there is still much to be deciphered in terms of regulation and action models in both preclinical and clinical research. MAPK has implications in the response to cancer therapy, particularly the activation of the compensatory pathways in response to experimental MAPK inhibition. The present paper discusses new insights into MAPK as a complex cell signaling pathway with roles in the sustenance of cellular normal conduit, response to cancer therapy, and activation of compensatory pathways. Unfortunately, most MAPK inhibitors trigger resistance due to the activation of compensatory feed-back loops in tumor cells and tumor microenvironment components. Therefore, novel combinatorial therapies have to be implemented for cancer management in order to restrict the possibility of alternative pathway activation, as a perspective for developing novel therapies based on integration in translational studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11101618

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 140 references

Research works printed but not linked: 9

  1. Cainap, 2016, Results of third-generation epirubicin/cisplatin/xeloda adjuvant chemotherapy in patients with radically resected gastric cancer, J. BU ON, 21, 349
  2. Irimie, 2015, Novel technologies for oral squamous carcinoma biomarkers in diagnostics and prognostics, Acta Odontol. Scand., 73, 161, 10.3109/00016357.2014.986754 · doi:10.3109/00016357.2014.986754
  3. Zhao, 2017, MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing beta-catenin nuclear accumulation, Oncol. Rep., 38, 3055, 10.3892/or.2017.5955 · doi:10.3892/or.2017.5955
  4. Ionescu, 2014, TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: A pilot study, J. Gastrointest. Liver Dis., 23, 413, 10.15403/jgld.2014.1121.234.smad · doi:10.15403/jgld.2014.1121.234.smad
  5. Mauro, 2017, Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors, Sci. Rep., 7, 9388, 10.1038/s41598-017-10062-1 · doi:10.1038/s41598-017-10062-1
  6. Zou, 2019, Mechanisms shaping the role of ERK1/2 in cellular senescence, Mol. Med. Rep., 19, 759
  7. Tomuleasa, 2012, Sorafenib for advanced-stage hepatocellular carcinoma, Eur. J. Gastroenterol. Hepatol., 24, 346, 10.1097/MEG.0b013e3283501a2e · doi:10.1097/meg.0b013e3283501a2e
  8. Pall, 2011, Establishment of an embryonic stem cell line from blastocyst stage mouse embryos, Rom. J. Morphol. Embryol., 52, 1005
  9. Susman, 2011, Pancreatic exocrine adult cells and placental stem cells co-culture. Working together is always the best way to go, Rom. J. Morphol. Embryol., 52, 999

Cited by

See all 944

Metadata

Authors
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., Ionescu, C., & Berindan-Neagoe, I.
Venue
Cancers
Publisher
MDPI AG
Published
2019-10-22
Volume
11
Issue
10
Pages
1618
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2982051641
Cited by
944
References
140
FWCI
26.28
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. https://app.cochat.ai/papers/10.3390/cancers11101618
The paper
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., Ionescu, C., & Berindan-Neagoe, I. (2019). A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers. https://doi.org/10.3390/cancers11101618

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.